-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Autolus Therapeutics, Lowers Price Target to $10

Benzinga·04/01/2025 13:02:18
Listen to the news
Truist Securities analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and lowers the price target from $11 to $10.